Replies to post #100384 on Biotech Values

[ThomasS]

MNTA: I believe the approval CC addressed this issue when asked by an analyst. You'd have to listen to the archived event.

[DewDiligence]

Reimbursement of NVS’ Lovneox costs (from MNTA CC):

• Reimbursement by MNTA of NVS’ Lovenox development costs is capped at 50% of MNTA’s cash flow from Lovenox during each quarter and will be deducted from NVS’s cash payments to MNTA during the quarter.

• MNTA expects the entire amount owed to NVS will be repaid (as described above) within three quarters.

[DewDiligence]

I can't find explicit language in the contract that requires Momenta to reimburse the development costs Sandoz picked up over the years.

I’m pretty sure the (redacted) provision of the NVS-MNTA agreement pertaining to reimbursement of NVS’ development costs is in the SEC filing I cited, but it’s now moot insofar as the disclosure in #msg-52868377 tells us everything we need to know.